Velasco-Velázquez’s study found that the CCL5-CCR5 axis is highly activated in TNBC− and human epidermal growth factor receptor-2 (HER2)-positive breast cancers and that CCR5+ cells respond to CCL5. This evidence concerns the gene CCR5 and breast carcinoma.